Observational studyThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2023
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
Observational study in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence.American journal of epidemiology · 2026Observational
- Outcomes in patients with multidrug- or rifampin-resistant tuberculosis treated with bedaquiline and/or delamanid under the South Korean nationwide approval process.BMC infectious diseases · 2026Article
- Sustained outcomes 3 years after all-oral 9-month regimen for rifampicin-resistant TB.IJTLD open · 2026Article
- Safety and Effectiveness of Contezolid versus Linezolid in Drug-Resistant Tuberculosis: A 12-Month Retrospective Study from China.Infection and drug resistance · 2026Article
- Treatment outcomes of short-regimen multi-drug resistant tuberculosis in uMkhanyakude district (2018-2022) South Africa: a retrospective, cross-sectional study.BMC infectious diseases · 2025Article
- Effectiveness of a bedaquiline, linezolid, clofazimine 'core' for multidrug-resistant TB.IJTLD open · 2025Article
- Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.Nature communications · 2024Observational
- Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Article
- Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.PLOS global public health · 2023Article
- Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline againstFrontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 13 institutions in 9 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.